Clinicopathological analysis and investigation of treatment-resistant mechanisms in small cell carcinoma of the uterine cervix

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09481
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: University of Occupational and Environmental Health, Japan
• Principal Investigator: Yoshino Kiyoshi 産業医科大学, 医学部, 教授 (90362730)
• Co-Investigator(Kenkyū-buntansha): 栗田 智子 産業医科大学, 医学部, 准教授 (30519864) ; 原田 大史 産業医科大学, 医学部, 講師 (10835820) ; 上田 豊 大阪大学, 大学院医学系研究科, 講師 (10346215)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 子宮頸部小細胞癌

Outline of Final Research Achievements

Small cell neuroendocrine carcinoma of the cervix (SCNEC) predominantly affects women of reproductive age and has a poor prognosis. It is therefore a tumor for which the development of effective treatment is desirable. At present, chemotherapy has been shown to play an important role in the management of cervical SCNEC. We collected cases of small cell carcinoma of the cervix in the Kitakyushu area and analyzed the relationship between clinicopathological features and treatment response. The results showed that among the treatment modalities of surgery, radiation and chemotherapy, the prognosis tended to be best when chemotherapy was incorporated. Anticancer drug sensitivity testing is possible in a 3D culture system using tumor tissue taken from cervical cancer tissue and should be further developed for clinical application.

Free Research Field

婦人科腫瘍

Academic Significance and Societal Importance of the Research Achievements

子宮頸部小細胞癌は通常の腺癌や扁平上皮癌と異なり前がん病変に関して存在の有無すら不明である。発症から進行が早く、まて検診での早期発見は不可能であることから、進行がんの治療の確立が求められる。我々の研究は有効な化学療法のレジメンを本研究の症例および過去の報告された論文から導き出し、患者に有効な治療手段を提示できる可能性が示された。また3D初代培養を応用し、患者に薬剤を投する前に感受性を推定できる可能性を示した。